Spyre Therapeutics Inc’s recent filing unveils that its Director Albers Jeffrey W. unloaded Company’s shares for reported $0.25 million on Nov 06 ’24. In the deal valued at $36.76 per share,6,700 shares were sold. As a result of this transaction, Albers Jeffrey W. now holds 27,360 shares worth roughly $0.75 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Albers Jeffrey W. sold 300 shares, generating $10,929 in total proceeds. Upon selling the shares at $36.43, the Director now owns 34,060 shares.
Before that, SESSIONS, LLC bought 7,000 shares. Spyre Therapeutics Inc shares valued at $235,900 were divested by the Director at a price of $33.70 per share.
Wedbush initiated its Spyre Therapeutics Inc [SYRE] rating to an Outperform in a research note published on September 04, 2024; the price target was $45. A number of analysts have revised their coverage, including Evercore ISI’s analysts, who began to cover the stock in mid July with a ‘”an Outperform”‘ rating. Robert W. Baird began covering SYRE with “an Outperform” recommendation on May 02, 2024. Wells Fargo revised its rating on March 01, 2024. It rated SYRE as “an Overweight” which previously was an “an Equal weight”.
Price Performance Review of SYRE
On Tuesday, Spyre Therapeutics Inc [NASDAQ:SYRE] saw its stock fall -1.37% to $27.27. Over the last five days, the stock has lost -1.94%. Spyre Therapeutics Inc shares have risen nearly 26.72% since the year began. Nevertheless, the stocks have risen 39.27% over the past one year. While a 52-week high of $47.97 was reached on 03/18/24, a 52-week low of $14.22 was recorded on 01/03/24. SMA at 50 days reached $31.02, while 200 days put it at $31.45.
Levels Of Support And Resistance For SYRE Stock
The 24-hour chart illustrates a support level at 26.45, which if violated will result in even more drops to 25.62. On the upside, there is a resistance level at 28.58. A further resistance level may holdings at 29.88. The Relative Strength Index (RSI) on the 14-day chart is 36.85, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.64, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 86.39%. Stochastics %K at 15.10% indicates the stock is a buying.
How much short interest is there in Spyre Therapeutics Inc?
A steep rise in short interest was recorded in Spyre Therapeutics Inc stocks on 2024-11-15, dropping by -0.37 million shares to a total of 8.04 million shares. Yahoo Finance data shows the prior-month short interest on 2024-10-15 was 8.41 million shares. There was a decline of -4.64%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on December 20, 2023 when BTIG Research began covering the stock and recommended ‘”a Buy”‘ rating along with a $32 price target.
